VIEWS: 1 PAGES: 2 POSTED ON: 2/27/2012
Another interesting study is called, -œUtility of D2-40, a novel mesothelial marker, in the diagnosis of malignant Mesothelioma-• by Albert Y Chu, Leslie A Litzky, Theresa L Pasha, Geza Acs and Paul J Zhang - Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA - Modern Pathology (2005) 18, 105-110. Here is an excerpt: -œAbstract - Although immunohistochemistry has proven to be valuable in the differentiation of epithelioid mesothelioma from pulmonary or metastatic adenocarcinoma, no single antibody has demonstrated absolute sensitivity or specificity in making this distinction. Using immunohistochemical analysis with D2-40, a recently available monoclonal antibody that has been used as a lymphatic endothelial marker, we examined 53 cases of mesothelioma, 28 cases of reactive pleura, 30 cases of pulmonary adenocarcinoma, 35 cases of renal cell carcinoma, 26 cases of ovarian serous carcinoma, 16 cases of invasive breast carcinoma, 11 cases of prostatic adenocarcinoma, and seven cases of urothelial carcinoma. In addition, immunohistochemistry using calretinin, cytokeratin 5/6, and WT1 was performed on all cases of mesothelioma, pulmonary adenocarcinoma, ovarian serous carcinoma, and renal cell carcinoma. Predominantly, membranous D2-40 immunoreactivity was present in 51 of 53 (96%) mesotheliomas, 27 of 28 (96%) cases of reactive pleura, and 17 of 26 (65%) ovarian serous carcinomas; membranous staining was not seen in any other tumors examined. Compared to other immunohistochemical markers of mesothelioma, D2-40 was as sensitive as calretinin and more sensitive than cytokeratin 5/6 and WT1. We conclude that D2-40 immunoreactivity is sensitive for cells of mesothelial origin, and may be useful in the differential diagnosis of epithelioid malignant mesothelioma vs adenocarcinoma.-• Another interesting study is called, -œThe Immunohistochemical Diagnostic Panel for Epithelial Mesothelioma: A Reevaluation After Heat-Induced Epitope Retrieval-• by Riera, Jose R. M.D.; Astengo-Osuna, Carlos M.D.; Longmate, Jeffrey A. Ph.D.; Battifora, Hector M.D - American Journal of Surgical Pathology: December 1997 - Volume 21 - Issue 12 - pp 1409-1419. Here is an excerpt: -œAbstract - The immunohistochemical diagnosis between epithelial mesothelioma and adenocarcinoma is currently based on the use of a panel of antibodies to adenocarcinoma-associated antigens and a few antibodies to mesothelial-associated antigens. Since the introduction of epitope retrieval methods, the sensitivity of many antibodies has been enhanced. Thus, a reevaluation of the mesothelioma/adenocarcinoma diagnostic panel becomes necessary. We studied 268 paraffin-embedded formalin-fixed tumor samples that included 57 epithelial mesotheliomas and 211 adenocarcinomas of various origins, comparing an extensive antibody panel with and without heat-induced epitope retrieval (HIER). Marked increase in the sensitivity of several antibodies, with no loss of specificity, was found when HIER was used. After statistical analysis, the antibodies to the epithelial glycoproteins carcinoembryonic antigen, BerEp4, and Bg8 emerged as the best discriminators between adenocarcinoma and epithelial mesothelioma within the entire panel. The mesothelium-associated antibodies, HBME-1, calretinin, and thrombomodulin were less sensitive and less specific than the former, although they were found to be useful on certain cases. Antibodies to cytokeratins and vimentin, although of minor diagnostic value in this context, may be helpful to evaluate the quality of antigen preservation. This study confirms the value of immunohistochemistry to accurately distinguish mesothelioma from adenocarcinoma when an antibody panel approach is used. The addition of heat-induced epitope retrieval methods increases the effectiveness of the procedure and is recommended for most of the antibody panel members.-• Another interesting study is called, -œA review of peritoneal mesothelioma at the Washington Cancer Institute.-• - Surg Oncol Clin N Am. 2003 Jul;12(3):605-21, xi. By Sugarbaker PH, Welch LS, Mohamed F, Glehen O. Here is an excerpt: -œAbstract - This article reviews a single institution's experience with 68 patients (21 females, 47 males) prospectively treated over the last 2 decades with an aggressive local- regional approach, combining maximal cytoreductive surgery with heated intraoperative intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy. This multimodality treatment has resulted in a median survival of 67 months. Female patients had a significantly better prognosis than males. The other significant predictive factors of survival were: age, diagnosis by incidental findings, tumor extent, pathology, and completeness of cytoreduction.-• We all owe a debt of gratitude to these fine researchers. If you found any of these excerpts interesting, please read the studies in their entirety. Monty Wrobleski is the author of this article. For more information please click on the following links Depuy Hip Recall Attorney Depuy Hip Recall Attorney Related Articles - Asbestos Exposure, Mesothelioma Cancer, asbestos attorney, lawyer, class action lawyers, law suit, suite, law firm, law firms, litigation, Treatment, , Email this Article to a Friend! Receive Articles like this one direct to your email box!Subscribe for free today!
Pages to are hidden for
"Immunohistochemical Analysis and Mesothelioma Disease (DOC)"Please download to view full document